New bipolar drug MK-8189 passes early safety check in small study
NCT ID NCT06273774
First seen May 04, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This early-stage study tested the safety and tolerability of the drug MK-8189 (elpipodect) in 34 adults with stable bipolar I disorder. Participants were in a non-acute phase of their illness and had previously tolerated antipsychotic medication. The study did not test whether the drug works; it only looked for side effects and how the body processes the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atlanta Center for Medical Research ( Site 0001)
Atlanta, Georgia, 30331, United States
-
Hassman Research Institute Marlton Site ( Site 0006)
Marlton, New Jersey, 08053, United States
-
Woodland International Research Group-Clinical Research ( Site 0009)
Little Rock, Arkansas, 72211, United States
Conditions
Explore the condition pages connected to this study.